ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0917

Synovial Tissue Neutrophils are Associated with Disease Activity and Early Remission in Rheumatoid Arthritis
Abstract Number: 0918

Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 0919

Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
Abstract Number: 0920

Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells
Abstract Number: 0921

Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Abstract Number: 0922

Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Abstract Number: 0923

Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Abstract Number: 0924

Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology
Abstract Number: 0925

Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
Abstract Number: 0926

Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Abstract Number: 0927

Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Abstract Number: 0928

Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
Abstract Number: 0929

SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
Abstract Number: 0930

Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Abstract Number: 0931

Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].